Effect of probucol on vascular remodeling due to atherosclerosis in rabbits: An intravascular ultrasound study

Chinese Medical Journal

Volumn 124, Issue 12, 2011, Pages 1840-1847

  Li, Ting Ting ^a   Xie, Yi ^b   Guo, Yuan ^a   Tian, Hong Bo ^c   Zhang, Jian Ning ^a   Peng, Jie ^a   Zhang, Yun ^a  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

^c SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Arteriosclerosis; Intravascular ultrasonography; Plaque; Probucol; Vascular remodeling

Indexed keywords

CATHEPSIN K; CATHEPSIN S; CYSTATIN C; GELATINASE A; GELATINASE B; PROBUCOL; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; APOPTOSIS; ARTICLE; ATHEROSCLEROTIC PLAQUE; BLOOD VESSEL DIAMETER; CELL INFILTRATION; CONTROLLED STUDY; DRUG EFFECT; EXTRACELLULAR MATRIX; GENE EXPRESSION; HISTOLOGY; IMMUNOHISTOCHEMISTRY; INTRAVASCULAR ULTRASOUND; MACROPHAGE; MALE; NONHUMAN; PROTEIN LOCALIZATION; SMOOTH MUSCLE FIBER;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; APOPTOSIS; ATHEROSCLEROSIS; LIPIDS; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; OXIDATIVE STRESS; PROBUCOL; RABBITS; ULTRASONOGRAPHY, INTERVENTIONAL;

EID: 79959504802     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.12.015     Document Type: Article

References (37)

1. Kita T, Nagano Y, Yokode M, Ishi K, Kume N, Ooshima A, etal. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc Natl Acad Sci USA 1987; 84: 5928-5931.
2. Carew TE, Schwenke DC, Steinberg D. Antiatherogenic effect of probucol unrelated to its hypercholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc Natl Acad Sci U S A 1987; 84: 7725-7729.
3. Daugherty A, Zweifel BS, Schonfeld G. Probucol attenuates the development of aortic atherosclerosis in cholesterol-fed rabbits. Br J Pharmacol 1989; 98: 612-618.
4. Chang MY, Sasahara M, Chait A, Raines EW, Ross R. Inhibition of hypercholesterolemia-induced atherosclerosis in the nonhuman primate by probucol: II. Cellular composition and proliferation. Arterioscler Thromb Vasc Biol 1995; 15: 1631-1640.
5. Sawayama Y, Shimizu C, Maeda N, Tatsukawa M, Kinukawa N, Koyanagi S, et al. Effects of probucol and pravastatin on common carotid atherosclerosis in patients with asymptomatic hypercholesterolemia. Fukuoka Atherosclerosis Trial (FAST). J Am Coll Cardiol 2002; 39: 610-616.
6. Yamashita S, Hbujo H, Arai H, Harada-Shiba M, Matsui S, Fukushima M, et al. Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan. J Atheroscler Thromb 2008; 15: 292-303.
7. Tagawa T, Urabe Y, Kimura Y, Suzuki S, Ono H, Takeda K. Long-term treatment with probucol improves endothelial function in patients with coronary artery disease. Hypertens Res 2004; 27: 311-318.
8. Deng YM, Wu BJ, Witting PK, Stocker R. Probucol protects against smooth muscle cell proliferation by upregulating heme oxygenase-1. Circulation 2004; 110: 1855-1860.
9. O'Brien K, Nagano Y, Gown A, Kita T, Chait A. Probucol treatment affects the cellular composition but not anti-oxidized low density lipoprotein immunoreactivity of plaques from Watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb 1991; 11: 751-759.
10. Ku G, Doherty NS, Schmidt LF, Jackson RL, Dinerstein RJ. Ex vivo lipopolysaccharide-induced interleukin-1 secretion from murine peritoneal macrophages inhibited by probucol, a hypocholesterolemic agent with antioxidant properties. FASEB J 1990; 4: 1645-1653.
11. Wu TC, Chen YH, Leu HB, Chen YL, Lin FY, Lin SJ, et al. Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis. Free Radic Biol Med 2007; 43: 1508-1522.
12. Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 2002; 90: 251-262.
13. Ivan E, Khatri JJ, Johnson C, Magid R, Godin D, Nandi S, etal. Expansive arterial remodeling is associated with increased neointimal macrophage foam cell content: the murine model of macrophage-rich carotid artery lesions. Circulation 2002; 105: 2686-2691.
14. Kuzuya M, Nakamura K, Sasaki T, Cheng XW, Itohara S, Iguchi A. Effect of MMP-2 deficiency on atherosclerotic lesion formation in apoE-deficient mice. Arterioscler Thromb Vasc Biol 2006; 26: 1120-1125.
15. Varnava AM, Mills PG, Davies MJ. Relationship between coronary artery remodeling and plaque vulnerability. Circulation 2002; 105: 939-943.
16. Schoenhagen P, Ziada KM, Kapadia SR, Crowe TD, Nissen SE, Tuzcu EM. Extent and direction of arterial remodeling in stable versus unstable coronary syndromes: an intravascular ultrasound study. Circulation 2000; 101: 598-603.
17. Nakamura M, Nishikawa H, Mukai S, Setsuda M, Nakajima K, Tamada H, et al. Impact of coronary artery remodeling on clinical presentation of coronary artery disease: an intravascular ultrasound study. J Am Coll Cardiol 2001; 37: 63-69.
18. Chen WQ, Zhang L, Liu YF, Chen L, Ji XP, Zhang M, et al. Prediction of atherosclerotic plaque ruptures with high frequency ultrasound imaging and serum inflammatory markers. Am J Physiol Heart Circ Physiol 2007; 293: H2836-H2844.
19. Mintz GS, Nissen SE, Anderson WD, Bailey SR, Erbel R, Fitzgerald PJ, et al. American College of Cardiology clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound studies (IVUS): a report of the American College of Cardiology task force on clinical expert consensus documents. J Am Coll Cardiol 2001; 37: 1478-1492.
20. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem 1979; 95: 351-358.
21. Wu BJ, Di Girolamo N, Beck K, Hanratty CG, Choy K, Hou JY, et al. Probucol [4,40-[(1-methylethylidene)- bis(thio)]bis-[2,6-bis(1,1-dimethylethyl)phenol]] inhibits compensatory remodeling and promotes lumen loss associated with atherosclerosis in apolipoprotein E-deficientmice. J Pharmacol Exp Ther 2007; 321: 477-484.
22. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation 2002; 105: 297-303.
23. Moghadasian MH, McManus BM, Godin DV, Rodrigues B, Frohlich JJ. Proatherogenic and antiatherogenic effects of probucol and phytosterols in apolipoprotein E deficient mice: possible mechanisms of action. Circulation 1999; 99: 1733-1739.
24. Bentzon JF, Pasterkamp G, Falk E. Expansive remodeling is a response of the plaque-related vessel wall in aortic roots of apoE-deficient mice: an experiment of nature. ArteriosclerThromb Vasc Biol 2003; 23: 257-262.
25. Liu J, Sukhova GK, Sun JS, Xu WH, Libby P, Shi GP. Lysosomal cysteine proteases in atherosclerosis. Arterioscler Thromb Vasc Biol 2004; 24: 1359-1366.
26. Pasterkamp G, Schoneveld AH, Hijnen DJ, de Kleijn DP, Teepen H, van der Wal AC, et al. Atherosclerotic arterial remodeling and the localization of macrophages and matrix metalloproteases 1, 2 and 9 in the human coronary artery. Atherosclerosis 2000; 150: 245-253.
27. Prescott MF, Sawyer WK, Von Linden-Reed J, Jeune M, Chou M, Caplan SL, et al. Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm inLDL receptor-deficient mice. Ann N Y Acad Sci 1999; 878: 179-190.
28. Karwowski JK, Markezich A, Whitson J, Abbruzzese TA, arins CK, Dalman RL. Dose-dependent limitation of arterial enlargement by the matrix metalloproteinase inhibitor RS-113,456. J Surg Res 1999; 87: 122-129.
29. Sukhova GK, Shi GP, Simon DI, Chapman HA, Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest 1998; 102: 576-583.
30. Shi GP, Sukhova GK, Grubb A, Ducharme A, Rhode LH, Lee RT, et al. Cystatin C deficiency in human atherosclerosis and aortic aneurysms. J Clin Invest 1999; 104: 1191-1197.
31. Ferns GA, Forster L, Stewart-Lee A, Nourooz-Zadeh J, Anggård EE. Probucol inhibits mononuclear cell adhesion to vascular endothelium in the cholesterol-fed rabbit. Atherosclerosis 1993; 100: 171-181.
32. Choy K, Beck K, Png FY, Wu BJ, Leichtweis SB, Thomas SR, et al. Processes involved in the site-specific effect of probucol on atherosclerosis in apolipoprotein E gene knockout mice. Arterioscler Thromb Vasc Biol 2005; 25: 684-1690.
33. Walsh K, Smith RC, Kim HS. Vascular cell apoptosis in remodeling, restenosis and plaque rupture. Circ Res 2000; 87: 184-188.
34. Durand E, Mallat Z, Addad F, Vilde F, Desnos M, Guérot C, et al. Time courses of apoptosis and cell proliferation and their relationship to arterial remodeling and restenosis after angioplasty in an atherosclerotic rabbit model. J Am Coll Cardiol 2002; 39: 1680-1685.
35. Sia YT, Lapointe N, Parker TG, Tsoporis JN, Deschepper CF, Calderone A, et al. Beneficial effects of long-term use of the antioxidant probucol in heart failure in the rat. Circulation 2002; 105: 2549-2555.
36. Clarke MC, Littlewood TD, Figg N, Maguire JJ, Davenport AP, Goddard M, et al. Chronic apoptosis of vascular smooth muscle cells accelerates atherosclerosis and promotes calcification and medial degeneration. Circ Res 2008; 102: 1529-1538.
37. Wu BJ, Kathir K, Witting PK, Beck K, Choy K, Li C, et al. Antioxidants protect from atherosclerosis by a heme oxygenase-1 pathway that is independent of free radical scavenging. J Exp Med 2006; 203: 1117-1127.